Movement Alert｜RemeGen Falls 5.01% in Regular Trading, Biotech Sector Broadly Weak After Recent Sharp Rally

Market Focus07-07

On July 7, RemeGen (09995.HK) fell 5.01% in regular trading, trading at HK$83.6/share, with turnover of HK$295 million.

The broader biotech sector experienced widespread selling pressure, with AKESO down 3.34%, Innovent Biologics down 2.43%, BeiGene down 2.10%, and KEYMED Biosciences down 1.90%. The pullback comes after a period of exceptionally strong gains for RemeGen, with its A-share listing surging over 31% in the prior week alone, driven by catalysts including new drug approvals for Telitacicept in Sjogren's syndrome and IgA nephropathy, and innovative drug payment reform policies.

Additionally, 193 million restricted shares (34.16% of total equity) were unlocked on July 1, though selling pressure remains structurally limited as shareholders are prohibited from reducing holdings via centralized bidding or block trades due to the company's cash dividend not meeting regulatory requirements. The sector-wide retreat and profit-taking after the recent rally appear to be the primary near-term headwinds.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1180812151?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-07 13:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180812151","market":"hk","top_or_hot":-1,"title":"Movement Alert｜RemeGen Falls 5.01% in Regular Trading, Biotech Sector Broadly Weak After Recent Sharp Rally","media":"Market Focus","content":"<p><p>On July 7, RemeGen (09995.HK) fell 5.01% in regular trading, trading at HK$83.6/share, with turnover of HK$295 million.</p><p>The broader biotech sector experienced widespread selling pressure, with AKESO down 3.34%, Innovent Biologics down 2.43%, BeiGene down 2.10%, and KEYMED Biosciences down 1.90%. The pullback comes after a period of exceptionally strong gains for RemeGen, with its A-share listing surging over 31% in the prior week alone, driven by catalysts including new drug approvals for Telitacicept in Sjogren's syndrome and IgA nephropathy, and innovative drug payment reform policies.</p><p>Additionally, 193 million restricted shares (34.16% of total equity) were unlocked on July 1, though selling pressure remains structurally limited as shareholders are prohibited from reducing holdings via centralized bidding or block trades due to the company's cash dividend not meeting regulatory requirements. The sector-wide retreat and profit-taking after the recent rally appear to be the primary near-term headwinds.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜RemeGen Falls 5.01% in Regular Trading, Biotech Sector Broadly Weak After Recent Sharp Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜RemeGen Falls 5.01% in Regular Trading, Biotech Sector Broadly Weak After Recent Sharp Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-07 13:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 7, RemeGen (09995.HK) fell 5.01% in regular trading, trading at HK$83.6/share, with turnover of HK$295 million.</p><p>The broader biotech sector experienced widespread selling pressure, with AKESO down 3.34%, Innovent Biologics down 2.43%, BeiGene down 2.10%, and KEYMED Biosciences down 1.90%. The pullback comes after a period of exceptionally strong gains for RemeGen, with its A-share listing surging over 31% in the prior week alone, driven by catalysts including new drug approvals for Telitacicept in Sjogren's syndrome and IgA nephropathy, and innovative drug payment reform policies.</p><p>Additionally, 193 million restricted shares (34.16% of total equity) were unlocked on July 1, though selling pressure remains structurally limited as shareholders are prohibited from reducing holdings via centralized bidding or block trades due to the company's cash dividend not meeting regulatory requirements. The sector-wide retreat and profit-taking after the recent rally appear to be the primary near-term headwinds.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1180812151","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180812151","pubTimestamp":1783401139,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 7, RemeGen (09995.HK) fell 5.01% in regular trading, trading at HK$83.6/share, with turnover of HK$295 million.The broader biotech sector experienced widespread selling pressure, with AKESO...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"动向提示|RemeGen常规交易下跌5.01%生物科技板块近期大涨后普遍疲软","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"On July 7, RemeGen (09995.HK) fell 5.01% in regular trading, trading at HK$83.6/share, with turnover of HK$295 million.The broader biotech sector experienced widespread selling pressure, with AKESO down 3.34%, Innovent Biologics down 2.43%, BeiGene down 2.10%, and KEYMED Biosciences down 1.90%. The pullback comes after a period of exceptionally strong gains for RemeGen, with its A-share listing surging over 31% in the prior week alone, driven by catalysts including new drug approvals for Telitacicept in Sjogren's syndrome and IgA nephropathy, and innovative drug payment reform policies.Additionally, 193 million restricted shares (34.16% of total equity) were unlocked on July 1, though selling pressure remains structurally limited as shareholders are prohibited from reducing holdings via centralized bidding or block trades due to the company's cash dividend not meeting regulatory requirements. The sector-wide retreat and profit-taking after the recent rally appear to be the primary near-term headwinds.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1180812151","isCrawlerRequest":true}